注射用細胞毒性薬の世界市場：2025年～2033年

注射用細胞毒性薬の世界市場は、2024年に131億2,000万米ドルに達し、2032年までには205億9,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは5.2%で成長すると予測されています。

注射用細胞毒性薬は、成長するがん細胞を死滅させるために化学療法でよく使用される薬剤です。これらの薬剤は特定の標的を持たず、急速に増殖する細胞を死滅させることで作用します。これらの薬剤は、細胞分裂と複製段階を阻害し、細胞のDNA合成、RNA転写、タンパク質産生、微小管構造損傷などを妨害します。注射用細胞毒性薬には様々なクラスがあり、アルキル化剤、代謝拮抗剤、微小管損傷剤、細胞毒性抗生物質、白金化合物、トポイソメラーゼ阻害剤などが含まれます。

市場力学：

促進要因と抑制要因

がんの罹患率と有病率の上昇

注射用細胞毒性薬は、さまざまながんの化学療法に広く使用されています。高齢化、ライフスタイルの変化、環境要因など様々なリスク要因により、世界的にがんの罹患率と有病率が上昇しています。がんの罹患率の増加に伴い、注射用細胞毒性薬を用いた化学療法の需要は今後増加すると予想されます。例えば、国際がん研究機関の予測によると、2022年には2,000万人のがん患者が報告されています。2030年の罹患数は2,410万人、2040年には2,990万人に増加すると予測されています。

さらに、新規免疫療法や標的療法の登場により、がん治療の情勢は近年劇的に変化しています。その市場牽引力は高いですが、化学療法剤との併用で処方されることが多いです。これは、がん治療における細胞毒性薬の重要な役割を反映しています。

細胞毒性薬に伴う副作用が市場の成長を抑制する可能性があります。

注射用細胞毒性薬は、特定の細胞を標的とせず、体内で急速に増殖する細胞を標的とします。これらの細胞には、新生物とは別に正常な健康細胞も含まれることがあります。その結果、治療を受けた患者は吐き気、嘔吐、脱毛、注射部位の組織損傷、骨髄抑制などの副作用を経験する可能性があります。長期的な副作用としては、心毒性、神経毒性、肺不全、腎不全などがあり、これらは患者にとって致命的です。このような副作用の多さは、患者のQOL（生活の質）に大きな影響を与え、将来的な採用にも大きな支障をきたす可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • がんの発生率と罹患率の上昇
    • 新製品承認の増加
  • 抑制要因
    • 細胞毒性薬に伴う副作用
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• 疫学
• 価格分析
• パイプライン分析
• 特許分析
• 規制分析

第6章 薬剤クラス別

• アルキル化剤
  • シクロホスファミド
  • イホスファミド
  • ブスルファン
  • その他
• 代謝拮抗物質
  • メトトレキサート
  • 5-フルオロウラシル
  • その他
• 微小管損傷剤
  • ビンクリスチン
  • ビンブラスチン
  • パクリタキセル
  • ドセタキセル
  • その他
• 細胞毒性抗生物質
  • ドキソルビシン
  • アクチノマイシンD
  • ダウノルビシン
  • その他
• プラチナ化合物
  • シスプラチン
  • カルボプラチン
  • その他
• トポイソメラーゼ阻害剤
• その他

第7章 用途別

• 白血病
• リンパ腫
• 乳がん
• 肺がん
• 卵巣がん
• 大腸がん
• 膵臓がん
• 自己免疫疾患
• その他

第8章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第9章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第10章 企業プロファイル

• Pfizer Inc.
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 会社の収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Bristol-Myers Squibb Company.
• Sandoz Group AG
• Fresenius Kabi AG
• Teva Pharmaceuticals USA, Inc.
• Viatris Inc.
• Amneal Pharmaceuticals LLC.
• Sun Pharmaceutical Industries Ltd.
• AdvaCare Pharma
• Sanofi
• 各市場参入企業に対しても同様のデータが提供されます。

第11章 付録

The global Injectable cytotoxic drugs market reached US$ 13.12 billion in 2024 and is expected to reach US$ 20.59 billion by 2032, growing at a CAGR of 5.2% during the forecast period 2025-2033.

Injectable cytotoxic drugs are the medication often used in chemotherapy to kill the growing cancerous cells. These drugs have no specific targets and act by killing the fast-growing cells. They interfere in the cell division and replication stages and disrupt cellular DNA synthesis, RNA transcription, protein production, microtubule structural damage, etc. There are various classes of injectable cytotoxic drugs, which include alkylating agents, antimetabolites, microtubule damaging agents, cytotoxic antibiotics, platinum compounds, topoisomerase inhibitors, etc.

Market Dynamics: Drivers & Restraints

The rising incidence and prevalence of cancer

Injectable cytotoxic drugs are widely used in the chemotherapy of various cancers. Globally the incidence and prevalence of cancer are rising, due to various risk factors such as the aging population, lifestyle changes, environmental factors, etc. As cancer incidence grows, the demand for chemotherapy with injectable cytotoxic drugs is anticipated to increase in the future. For instance, as per the International Agency for Research on Cancer projections, in 2022, 20 million cancer cases were reported. The incidence cases in 2030 are expected to rise to 24.1 million in 2030 and 29.9 million in 2040.

Moreover, the cancer treatment landscape has drastically changed in recent years due to the launch of novel immunotherapies and targeted therapies. Although their market traction is high, they are often prescribed in combination with chemotherapeutic agents. This reflects the important role of cytotoxic drugs in cancer treatment.

Adverse effects associated with cytotoxic drugs may restrain the market growth.

Injectable cytotoxic drugs do not have a specific cell target, they target rapidly growing cells inside the body. These can also include normal healthy cells apart from neoplasms. As a result, the treated patient may experience adverse effects such as nausea, vomiting, hair loss, tissue damage at the site of injection, and bone marrow suppression. The long-term adverse effects include cardiotoxicity, neurotoxicity, lung failure, kidney failure, etc. which are fatal to the patient. This plethora of adverse effects can significantly affect the patient's quality of life, and can drastically hinder their adoption in the future.

Segment Analysis

The global injectable cytotoxic drugs market is segmented based on drug class, application, and region.

Platinum compounds in the drug class segment are expected to grow with the highest CAGR in the forecast period.

Platinum compounds are a class of cytotoxic agents that find their major application in cancer chemotherapy. These include drugs like cisplatin, carboplatin, and oxaliplatin which act by inhibiting the DNA synthesis and by cross-linking the DNA strands. These platinum compounds are efficacious in malignant cancers like breast, ovarian, lung, testicular, bladder, and colorectal cancers. Among the platinum compounds, cisplatin was the first approved drug, however, due to its adverse effects newer agents such as carboplatin and oxaliplatin were introduced into the market, which have significantly less adverse effect profile, and offer therapeutic beneficence.

These drugs are often used in combination with targeted therapies, immunotherapies, and other chemotherapeutic agents. Platinum compounds are also capable of treating certain cancers when prescribed as monotherapy. These drugs are also used in pediatric cases, and they drastically improve the survival rate. For instance, in April 2024, an article published in the American Journal of Clinical Oncology stated that platinum compounds increased survival rates in children with solid tumors such as osteosarcoma, neuroblastoma, retinoblastoma, germ cell tumors, etc.

As the incidence of these cancers rises, the adoption of platinum compounds is expected to significantly rise in the forecast period.

Geographical Analysis

North America is expected to hold a significant share of the Injectable cytotoxic drugs market.

North America region dominates the market due to its advanced healthcare infrastructure combined with the significant burden of cancer cases. For instance, as per the International Agency for Research on Cancer statistics, more than 2.6 million new cancer cases were reported in the North America region in 2022. Moreover, 3.1 million new cases in 2030, and 3.6 million new cases in 2040 are expected to be reported in the region. This rising burden of disease is expected to significantly raise the demand for cytotoxic drugs in the future.

Additionally, due to high awareness among the patient population in the region, they are diagnosed at early stages and receive cancer chemotherapy at the earliest. This reflects the higher treatment rates among cancer patients, as compared to other high-income countries.

In addition, the region has a strong presence of market players such as Pfizer, Bristol Myers Squibb Company, Viatris, Teva, Sandoz, etc. who generate higher revenue from sales of their products. For Instance, one of the most commonly used injectable cytotoxic drugs i.e., paclitaxel sold under the brand name ABRAXANE, manufactured by Bristol-Myers Squibb Company has generated a sales value of US$ 1 billion in 2023. Among this US$ 1 billion, ~ 70% is generated from the U.S. market.

Competitive Landscape

The major global players in the Injectable cytotoxic drugs market are Pfizer Inc., Bristol-Myers Squibb Company., Sandoz Group AG, Fresenius Kabi AG, Teva Pharmaceuticals USA, Inc., Viatris Inc., Amneal Pharmaceuticals LLC., Sun Pharmaceutical Industries Ltd., AdvaCare Pharma, and Sanofi among others.

Key Developments

• In October 2024, Sandoz launched a generic paclitaxel formulation in the U.S. market which has become the first generic version of its Abraxane approved by the U.S. FDA. The drug is available in injectable suspension (albumin-bound) and is indicated for metastatic breast cancer patients.
• In August 2024, Lupin Limited launched Doxorubicin Hydrochloride liposome injection single-dose vials in the U.S. market. The launch is based on ANDA approval from the U.S. FDA provided to ForDoz Pharma Corporation, an alliance partner of Lupin in the U.S.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming pharmaceutical advancements.
• Drug Class Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Drug Class delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Injectable cytotoxic drugs market report would provide approximately 54 tables, 52 figures, and 165 pages.

Drug Class Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Drug Class
• 3.2. Snippet by Application
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Rising Incidence and Prevalence of Cancers
    • 4.1.1.2. Rising New Product Approvals
  • 4.1.2. Restraints
    • 4.1.2.1. Adverse Effects Associated with Cytotoxic Drugs
  • 4.1.3. Opportunities
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Epidemiology
• 5.3. Pricing Analysis
• 5.4. Pipeline Analysis
• 5.5. Patent Analysis
• 5.6. Regulatory Analysis

6. By Drug Class

• 6.1. Introduction
  • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 6.1.2. Market Attractiveness Index, By Drug Class
• 6.2. Alkylating Agents*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.2.3. Cyclophosphamide
  • 6.2.4. Ifosfamide
  • 6.2.5. Busulfan
  • 6.2.6. Others
• 6.3. Antimetabolites
  • 6.3.1. Methotrexate
  • 6.3.2. 5-Fluorouracil
  • 6.3.3. Others
• 6.4. Microtubule Damaging Agents
  • 6.4.1. Vincristine
  • 6.4.2. Vinblastine
  • 6.4.3. Paclitaxel
  • 6.4.4. Docetaxel
  • 6.4.5. Others
• 6.5. Cytotoxic Antibiotics
  • 6.5.1. Doxorubicin
  • 6.5.2. Actinomycin D
  • 6.5.3. Daunorubicin
  • 6.5.4. Others
• 6.6. Platinum Compounds
  • 6.6.1. Cisplatin
  • 6.6.2. Carboplatin
  • 6.6.3. Others
• 6.7. Topoisomerase Inhibitors
• 6.8. Others

7. By Application

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 7.1.2. Market Attractiveness Index, By Application
• 7.2. Leukemia*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Lymphoma
• 7.4. Breast Cancer
• 7.5. Lung Cancer
• 7.6. Ovarian Cancer
• 7.7. Colorectal Cancer
• 7.8. Pancreatic Cancer
• 7.9. Autoimmune Conditions
• 7.10. Others

8. By Region

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 8.1.2. Market Attractiveness Index, By Region
• 8.2. North America
  • 8.2.1. Introduction
  • 8.2.2. Key Region-Specific Dynamics
  • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.2.5.1. U.S.
    • 8.2.5.2. Canada
    • 8.2.5.3. Mexico
• 8.3. Europe
  • 8.3.1. Introduction
  • 8.3.2. Key Region-Specific Dynamics
  • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.3.5.1. Germany
    • 8.3.5.2. U.K.
    • 8.3.5.3. France
    • 8.3.5.4. Spain
    • 8.3.5.5. Italy
    • 8.3.5.6. Rest of Europe
• 8.4. South America
  • 8.4.1. Introduction
  • 8.4.2. Key Region-Specific Dynamics
  • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.4.5.1. Brazil
    • 8.4.5.2. Argentina
    • 8.4.5.3. Rest of South America
• 8.5. Asia-Pacific
  • 8.5.1. Introduction
  • 8.5.2. Key Region-Specific Dynamics
  • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 8.5.5.1. China
    • 8.5.5.2. India
    • 8.5.5.3. Japan
    • 8.5.5.4. South Korea
    • 8.5.5.5. Rest of Asia-Pacific
• 8.6. Middle East and Africa
  • 8.6.1. Introduction
  • 8.6.2. Key Region-Specific Dynamics
  • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
  • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application

9. Competitive Landscape

• 9.1. Competitive Scenario
• 9.2. Market Positioning/Share Analysis
• 9.3. Mergers and Acquisitions Analysis

10. Company Profiles

Key Market Players

• 10.1. Pfizer Inc.*
  • 10.1.1. Company Overview
  • 10.1.2. Product Portfolio
    • 10.1.2.1. Product Description
    • 10.1.2.2. Product Key Performance Indicators (KPIs)
    • 10.1.2.3. Historic and Forecasted Product Sales
    • 10.1.2.4. Product Sales Volume
  • 10.1.3. Financial Overview
    • 10.1.3.1. Company Revenue's
    • 10.1.3.2. Geographical Revenue Shares
    • 10.1.3.3. Revenue Forecasts
  • 10.1.4. Key Developments
    • 10.1.4.1. Mergers & Acquisitions
    • 10.1.4.2. Key Product Development Activities
    • 10.1.4.3. Regulatory Approvals etc.
  • 10.1.5. SWOT Analysis
• 10.2. Bristol-Myers Squibb Company.
• 10.3. Sandoz Group AG
• 10.4. Fresenius Kabi AG
• 10.5. Teva Pharmaceuticals USA, Inc.
• 10.6. Viatris Inc.
• 10.7. Amneal Pharmaceuticals LLC.
• 10.8. Sun Pharmaceutical Industries Ltd.
• 10.9. AdvaCare Pharma
• 10.10. Sanofi
• Similar data will be provided for each market player.

LIST NOT EXHAUSTIVE

11. Appendix

• 11.1. About Us and Services
• 11.2. Contact Us